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Abstract
Background: There are no effective methods of diagnosis of early-stage ovarian cancer. Conservative care over
patients at high risk of ovarian and breast cancers is ineffective. Prophylactic surgery is considered the best
prophylaxis among BRCA1/BRCA2 carriers.
Methods: One hundred ninety-five patients, carriers of one of three most common mutations of the BRCA1 gene
(Am J Hum Genet: 66: (6)1963-1968, 2000) in the Polish population (5382insC, 4153delA and C61G), who undergone
prophylactic salpingo-oophorectomy. The study group consisted of consecutive mutation carriers living in Poland,
in the West Pomeranian province. Histopathological examination of the surgical material failed to reveal presence
of malignancy.
Results: During follow-up we diagnosed two peritoneal cancers and 14 breast cancers. Diagnosis of breast cancer
before prophylactic surgery increased the risk of peritoneal cancer almost three times. Time from diagnosis of
breast cancer to prophylactic surgery increased the risk of peritoneal cancer after prophylactic surgery. This was
strongly expressed (HR = 5.0; p = 0.030) in cases of over five-year-long delay in prophylactic surgery. Diagnosis of
breast cancer before prophylactic surgery correlated with the risk of death (p = 0.00010). Presence of 5382insC
mutation decreased and C61G mutation increased the risk of peritoneal cancer (p = 0.049 vs. p = 0.013).
Conclusions: Occurrence of primary peritoneal cancer after prophylactic surgery is similar to that reported in
international literature. Primary breast cancer occurred less often than in international literature. We suspect that the
risk of development of breast cancer among BRCA1 carriers undergoing prophylactic surgery can differ in a
population. The next goal should be to study the molecular basis for the risk of development of malignancies in
any population. Carriers of BRCA1 gene diagnosed with breast cancer should undergo prophylactic surgery within
five years from the diagnosis of breast cancer.
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Background
At the current state of knowledge there are no effective
methods enabling identification of ovarian cancer at an
early stage [1–5]. Conservative methods of prevention
also failed to reduce the mortality due to ovarian cancer
in a group of high-risk patients – carriers of the BRCA1
or BRCA2 gene mutations [6–13]. Other methods of
conservative care over high-risk of ovarian and breast
cancer patients(BRCA1 or BRCA2 carriers) have proven
ineffective [1, 11, 14, 15].
According to international literature prophylactic
surgery, referred to as PBSO (Prophylactic Bilateral
Salpingo-Oophorectomy), RRSO (Risk-Reducing Salpingo-
Oophorectomy), RRBSO (risk-reducing bilateral salpingo-
oophorectomy) or BSO, is currently considered the
best prophylaxis among BRCA1/BRCA2 mutation
carriers [1, 16–20].
In BRCA1/BRCA2 mutation carriers, PBSO/RRSO not
only decreases the risk of development of ovarian cancer
by 80-90 % and breast cancer by 40–50 %, but also re-
duces mortality due to cancer of the genital tract and
overall mortality [21–24].
According to Kotsopoulos et al., salpingo-oophorectomy
is equally effective in prevention of breast cancer in
women after natural menopause (p = 0.006) [25]. More-
over, prophylactic salpingo-oophorectomy protects pa-
tients with breast cancer who are also BRCA1/BRCA2
carriers from developing ovarian cancer. Metcalfe et al.
demonstrated that 25 % of deaths in this group of pa-
tients, particularly with a diagnosis of stage 1 breast
cancer, is caused by ovarian cancer. The fact that in this
group of patients systemic treatment did not signifi-
cantly influence the risk of development of ovarian can-
cer [26] is also an argument in favor of prophylactic
surgery.
In this work we present the results of our observations
in patients with mutation in BRCA1 gene after prophy-
lactic genital tract surgery in relation to development of
peritoneal or breast cancers. We assessed selected risk
factors for peritoneal cancer and compared chosen
characteristics depending on the presence or absence of
breast cancer diagnosis in a group of patients before
prophylactic surgery.
Goal:
1. To assess the incidence of peritoneal and breast
cancer among carriers of the BRCA1
gene mutation after prophylactic
salpingo-oophorectomy.
2. To analyze selected risk factors for peritoneal cancer
in patients after prophylactic surgery.
3. To assess selected characteristics among patients
subjected to surgery depending on the diagnosis
of breast cancer before prophylactic operation.
Methods
The material consisted of 195 patients, carriers of one of
three mutations in BRCA1 gene most commonly occurring
in the Polish population (5382insC, 4153delA and C61G)
[27], subjected to prophylactic salpingo-oophorectomy. Pa-
tients underwent prophylactic surgery over a period from
15 Sept 1999 to 31 Dec 2010. Study included consecutive
mutation carriers from the West Pomeranian province,
Poland, treated with surgery at the Department and Clinic
of Surgical Gynecology and Gynecological Oncology
(adults and children) of the Pomeranian Medical Univer-
sity in Szczecin, who were not diagnosed with malignancy
in histopathological examination of excised material.
Median age of patients at the time of surgery was
47 years (31–78 years). Median follow-up time was
80 months (4–153 months).
As much as 41.03 % (80/195) of patients were treated
for breast cancer before prophylactic surgery. Patients
who had been treated for breast cancer before prophy-
lactic surgery were undergoing prophylactic salpingo-
oophorectomy at an older age than patients without the
diagnosis of breast cancer before surgery. Both patients
diagnosed with primary peritoneal cancer after prophy-
lactic surgery, aside from salpingo-oophorectomy, had
undergone hysterectomy. Proportions of specific BRCA1
mutations were the following: 65.64 % (128/195) of pa-
tients were 5382insC carriers, 24, 62 % (48/195) had
C61G mutation, and 9.74 % (19/195) subjects had muta-
tion of the 4153 DelA type. As much as 6.67 % (13/195)
of patients died during follow-up.
Statistical analysis
All continuous variables were checked for normal distri-
bution with Kolmogorov-Smirnov test. Such variables
were described as means, standard deviations, medians,
quartiles, as well as minimal and maximal values. Statis-
tical differences between two groups were checked using
Student’s t test or Mann-Whitney’s test. Non-continuous
variables were described through absolute numbers and
frequency of occurrence. Pearson’s χ2 test or exact Fish-
er’s test were used to assess the relationship between
non-continuous variables.
A logistic regression model was used in order to assess
the risk of occurrence of a pathology depending on the
presence of various factors. Results were described by
relative risk (OR) with 95 % confidence interval and a p-
value indicating statistical significance. In this model,
probability was assessed using Pearson’s χ2 test or Fisher’s
exact two-tailed test.
Differences were considered statistically significant in
all conducted tests with p < 0.05. Level of statistical sig-
nificance p = 0.051-0.099 was considered a trend with
borderline statistical significance.
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Statistical analyses were performed using STATA 11
software (license no. 30110532736). The bioethics com-
mittee of the Pomeranian Medical University approved
(ref. no. BN-001/202/03) for the research to be carried
out.
Results
During the follow-up time (median time was 80 months)
there were 2 (2/195) cases of primary peritoneal cancer,
14 (14/195) cases of breast cancer, including 9 (9/195)
primary cancers (Table 1), diagnosed in our group of
BRCA1 mutation carriers subjected to prophylactic
salpingo-oophorectomy.
All breast cancers as well as primary breast cancers
were diagnosed in our material more frequently than
peritoneal cancer and that difference was statistically sig-
nificant, with p = 0.0022 (OR = 7.46; 95 % CI: 1.67–68.29)
vs. p = 0.0323 (OR = 4.67; 95 % CI: 1.10–44.10). Primary
breast cancer was 2.27 times more frequent than breast
cancer recurrence, but that relationship was not statisti-
cally significant (OR = 2.27; 95 % CI: 0.71–8.49).
Time of cancer diagnosis after prophylactic surgery
was significantly shorter among patients with 5382insC
mutation compared with C61G and 4153DelA mutations
combined, p = 0.0271 (median: 23 vs. 62 months).
Diagnosis of breast cancer in a patient before prophylac-
tic surgery increased the risk of peritoneal cancer almost
three times, but this characteristic was on the border of
statistical significance (p = 0.088). Carrying a 5382insC
mutation decreased the probability of peritoneal cancer,
while C61G mutation increased such likelihood, p = 0.049
and p = 0.013, respectively. Among carriers of 4153DelA
mutation the risk of development of peritoneal cancer was
neither increased nor decreased; that characteristic was
not statistically significant (Table 2).
Time from the diagnosis of breast cancer in a patient
before prophylactic surgery to the procedure itself was a
feature increasing the risk of peritoneal cancer in a sig-
nificant manner. That characteristic was particularly
strong (HR = 5.0; p = 0.030) in cases where the decision
of prophylactic surgery was delayed by more than five
years (Table 3).
Among all features selected for analysis among BRCA1
carriers diagnosed with breast cancer before prophylactic
surgery, only the survival feature was statistically signifi-
cant (p = 0.00010). Patients diagnosed with cancer before
prophylactic surgery died more frequently. In that group
of patients increased probability of development of any
cancer or peritoneal cancer was on the border of statis-
tical significance. Remaining features subjected to ana-
lysis, including type of mutation, were not statistically
significant (Table 4).
Discussion
In 1982 Jeanne Tobacman et al. described the first three
cases of peritoneal cancer after prophylactic oophorec-
tomy among 28 patients from families at high risk of
ovarian cancer [28]. Many studies have been published
since then. Sitzmann and Wiebke [29] point to several
important facts in one of the most recent metaanalyses
evaluating, among other things, the frequency of occur-
rence of peritoneal cancer after salpingo-oophorectomy
in patients with BRCA1/BRCA2 mutation. Firstly, a great
majority of authors report the number of diagnosed
peritoneal cancers at a level of 0.8–1.8 % [22, 30–36].
Casey et al. diagnosed 5 cases of peritoneal cancer
among 118 carriers of BRCA1 mutation. In one case the
patient had undergone oviduct-sparing surgery [37].
Among three cases of peritoneal cancer diagnosed in
BRCA1 carriers after PBSO, Mæhle et al. associated that
fact with presence of ovarian tissue left behind after previ-
ous surgeries [38]. Oliver et al. diagnosed 11.5 % (3/26 –
BRCA1 mutation) of peritoneal cancers after prophylactic
surgery, but the study group consisted of patients after
oviduct-sparing surgery. In the second group of patients
subjected to salpingo-oophorectomy the same authors did
not find any cases of peritoneal cancer during the follow-
up period (0/58 – BRCA1). However, researchers admit
that it might have been due to very short mean follow-up
time, which amounted to 12 months [39]. Likewise, after
16 months of follow-up, Gaarenstroom et al. did not diag-
nose peritoneal cancer in any of 114 patients (57 patients
were carriers of BRCA1 mutation) following prophylactic
salpingo-oophorectomy [40].
Table 1 Number of cancers and type of organ affected by cancer in patients followed up after prophylactic surgery
No.





and breast cancers %/(n)
Total %/(n)
Organ
Peritoneum 1.03 % (2/195) - - 5.64 % (11/195) 8.21 % (16/195)
Breast Primary 3.08 %(6/195) 4.63 %(9/195) 7.18 %(14/195)
II – primary 1.54 % (3/195)
Recurrence 2.56 % (5/195) N/A N/A
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Laki et al. did not find any cases of peritoneal cancer
among their patients following mean follow-up time of
40 months either [41]. Similarly, there were no cases of
primary peritoneal cancer in an 8.17-year follow-up in a
study by Evans et al. that included BRCA1/BRCA2 mu-
tation carriers (160 patients, including 104 subjects with
BRCA1 mutation) after salpingo-oophorectomy [42].
Authors who failed to find cases of peritoneal cancer
after prophylactic salpingo-oophorectomy most often ex-
plain it by short follow-up time. Such an argument is no
longer valid for the analysis of work by Evans et al. Small
size of the group is also often given as a reason for the
lack of such a finding [42].
In our analysis we acquired a result almost identical
with regard to the frequency of diagnosis of peritoneal
cancer among patients after salpingo-oophorectomy to
that obtained by Rhiem et al. – 1.03 % vs. 1.09 % (2/195
vs. 1/92 – BRCA1 gene mutations). The time of the first
diagnosis of peritoneal cancer was also similar – in our
material it amounted to 30 months, while according to
Rhiem et al. – 26 months [34]. In our study the second
peritoneal cancer was diagnosed after 62 months.
The second, very important conclusion ensuing from this
research is such that after prophylactic surgery peritoneal
cancer develops more frequently in BRCA1 mutation car-
riers. Peritoneal cancer was very rare among patients with
BRCA2 mutation. In their metaanalysis, Sitzmann and
Wiebke [29] presented results of 12 research teams and in
only one study by Finsch et al. peritoneal cancer was found
in a patient with a mutation in the BRCA2 gene [33].
However, it should be emphasized, that while there are
thousands of examined patients and mean follow-up
time from prophylactic surgery to the diagnosis of peri-
toneal cancer exceeds 6 years, the proportion of mutations
in both BRCA genes found in patients with primary peri-
toneal cancer diagnosed after salpingo-oophorectomy has
evidently changed – 28 BRCA1 vs. BRCA2 [21].
Due to a small number of subjects after prophylactic
surgery with BRCA2 gene mutation, we did not take
their data into consideration.
In our material we diagnosed 14 cases (14/195 =
7.18 %) of breast cancer, including 6 cases in patients
without the diagnosis of breast cancer before prophylac-
tic surgery, 3 cases of second primary breast cancer and
5 cases of breast cancer recurrence. Thus, primary
breast cancers identified during the follow-up time con-
stituted only 4.63 % (9/195) of all cases (Table 1).
Results obtained for primary breast cancers in our ma-
terial were somewhat smaller than values reported by
Casey et al. – 4.63 % vs. 5.93 % (7/118 – BRCA1 mutation)
over a shorter median follow-up time – 6.67 vs. 8.3 years,
respectively [37].
Similar overall results were obtained by Kauff et al.–
7.89 % (15/190 – BRCA1 mutation), with mean follow-up
Table 2 Risk of occurrence of peritoneal cancer in the whole group of patients (n = 195) depending on the characteristics assessed
with Cox regression model
Data
Risk factors HR 95 % CI p
Dependent variable
Peritoneal cancer Breast cancer before surgery 2.95 0.75 175.43 0.088
Age at time of surgery (years) 1.15 0.96 1.37 0.125
5382insC mutation 0.25 0.00 0.99 0.049
C61G mutation 6.39 1.62 379.51 0.013
4153DelA mutation 0.90 0.07 18.50 0.641
Table 3 Risk of occurrence of peritoneal cancer in the group of patients with diagnosed breast cancer before prophylactic surgery
(n = 80) depending on the characteristics assessed with Cox regression model
Data
Characteristic Risk factor HR CI 95 % p
Dependent variable
Peritoneal cancer Time from diagnosis of breast cancer prior to prophylactic
surgery to prophylactic surgery
Years 1.14 1.00 1.29 0.043
Time from diagnosis of breast cancer prior to prophylactic
surgery to prophylactic surgery
Years > =5 vs. <5 5.00 1.23 300.17 0.030
Age at the moment of breast cancer diagnosis in a patient
before prophylactic surgery
Years 0.93 0.75 1.14 0.488
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time shorter almost by half [32], and Powell et al. – 6.35 %
(4/63) among BRCA1 carriers, with median observation
time almost 1/3 shorter compared to our study. More-
over, in a detailed analysis researchers emphasize that
most of these cases were breast cancer recurrences
[36]. Domchek et al. acquired significantly higher re-
sults with respect to breast cancer diagnoses among
BRCA1 mutation carriers subjected to prophylactic
salpingo-oophorectomy over an almost 5-year-long
mean follow-up time – 13.6 % (51/374 – BRCA1).
Moreover, quantitative values were comparable regard-
less of a diagnosis of breast cancer before prophylactic
surgery [22].
Similarly high values were obtained by Fakkert et al. –
11.54 % (12/104 – BRCA1) over a median 3-year observation
time [43] and Laki et al. – 10.71 % (6/56 – BRCA1) [41].
Ramon Y Cajal et al. presented very high quantitative
values – researchers diagnosed as many as 5 cases of
breast cancer among 25 carriers of BRCA1 gene muta-
tion (20 %–5/25) subjected to prophylactic salpingo-
oophorectomy. In that case median follow-up time was
49 months [44].
Likewise, a very high (over 20 %) proportion of breast
cancer diagnoses among BRCA1 mutation carriers after
prophylactic bilateral oophorectomy was obtained by
Shah et al. with a median follow-up time from surgery
to the diagnosis of cancer amounting to 3.6 years [45].
Available literature is in agreement with regard to
higher incidence of breast cancer than peritoneal cancer
among BRCA1 carriers undergoing prophylactic salpingo-
oophorectomy [22, 32, 36, 41, 43].
Since the differing results of studies on breast cancer
in BRCA1 carriers undergoing prophylactic salpingo-
oophorectomy came from multi-center, multi-national
trials performed in various countries: USA, Canada,
Netherlands, France, Norway, Spain, Australia and New
Zeeland, we believe that it is necessary to examine mo-
lecular background in all populations, particularly for
such a common malignancy as breast cancer.
There were few publications on the influence of breast
cancer diagnosis among BRCA1 gene mutation carriers
before prophylactic surgery and the incidence of periton-
eal cancer in the postoperative period. There are also
few publications regarding the influence of the time
from diagnosis of breast cancer to prophylactic surgery
and the diagnosis of peritoneal cancer in the postopera-
tive period.
In our material the diagnosis of breast cancer before
prophylactic surgery was associated with an almost
three-fold increase in the risk of peritoneal cancer. How-
ever, that correlation was not statistically significant.
Domchek et al. acquired an opposite result. Peritoneal
cancer was found less often in patients with BRCA1 mu-
tation and breast cancer diagnosis before surgery than in
patients without breast cancer prior to surgery – 1.18 %
vs. 1.75 %. Researchers demonstrated also that prophy-
lactic salpingo-oophorectomy decreased the risk of pri-
mary peritoneal cancer among patients without previous
diagnosis of breast cancer by 70 % and in patients diag-
nosed with breast cancer prior to prophylactic surgery
by 85 % [22].
In our opinion, dissimilarities in our conclusions with
regard to the risk of development of peritoneal cancer
among patients without the diagnosis of breast cancer
prior to prophylactic surgery may ensue from different
numbers of diagnosed peritoneal cancer cases – 2 vs. 10
patients in a study by Domchek et al. Moreover, in our
study both patients diagnosed with primary peritoneal
cancer, who had been treated for breast cancer prior to
prophylactic surgery, decided to have the salpingo-
oophorectomy performed after the age of 50. Therefore,
surgery might no longer serve a protective role in devel-
opment of peritoneal cancer postoperatively.
Continuing the subject of the influence of breast cancer
diagnosis before prophylactic surgery, among six analyzed
features we found only the risk of death to be statistically
significant. Patient survival after prophylactic surgeries
will be the subject of another publication.
Table 4 Evaluation of selected characteristics among patients depending on the diagnosis of breast cancer before prophylactic
surgery
Characteristic Breast cancer before surgery
Not identified n = 115 Identified n = 80 N p
Death 1 0.87 % 12 15.00 % 13 p = 0.00010
Development of cancer 6 5.22 % 10 12.50 % 16 p = 0.06835
Development of peritoneal cancer 0 0.00 % 2 2.50 % 2 p = 0.08832
Development of breast cancer 6 5.22 % 8 10.00 % 14 p = 0.20318
Development of primary breast cancer 6 5.22 % 3 3.75 % 9 p = 0.63096
5382insC 78 67.83 % 50 62.50 % 128 p = 0.44111
Type of mutation C61G 24 20.87 % 24 30.00 % 48 p = 0.14543
4153DelA 13 11.30 % 6 7.50 % 19 p = 0.37823
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The topic of the influence of BRCA1 gene mutation
on examined characteristics is highly problematic to dis-
cuss. Although the type of mutation most commonly
identified in Polish population - 5382insC – is also found
among Jewish people, Ashkenazi Jews in particular [46],
available literature lacks the data for discussion.
Conclusions
Based on the analysis of gathered material and existing
literature we found that in our data the incidence of pri-
mary peritoneal cancer after prophylactic surgery is
similar to that reported in international literature. What
differs our material from reports in international litera-
ture is the occurrence of primary breast cancer – it was
significantly less frequent. Another conclusion is that it
cannot be excluded that the risk of breast cancer devel-
opment among constitutional BRCA1 gene mutation
carriers subjected to prophylactic surgery varies in a
population. The next goal in research should be to
examine molecular background with regard to the risk
of malignancy in every population. It is also important
that carriers of the BRCA1 gene mutation diagnosed
with breast cancer should be subjected to prophylactic
surgery within less than five years from the diagnosis of
breast cancer, as the risk of peritoneal cancer increases
significantly after that period.
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